Signal active
Contact Information
Social
Primary Organization
2012
51-100
Biotechnology, Pharmaceutical, Medical, Medical Device, Oncology
Bio
Maryvonne Hiance specializes in nuclear science and served, for 14 years, as manager of neutron studies at FRAMATOME (Areva). Over a 20-year period, she held the position of General Manager at innovative biotechnology companies including SangStat Atlantic, DrugAbuse Sciences and TcLand. She also founded and served as General Manager of Strategic Ventures, a consulting company providing support to technological companies.
Maryvonne Hiance has been a member of the French Strategic Council for Innovation and has served as Advisor to the French SMEs and Industry Ministry.
In 2008, she co-founded and served as CEO for Effimune, a biotechnology company specialized in immune regulation with clinical applications in autoimmunity, transplantation and immuno-oncology. Since the merger of Effimune with OSE Pharma in 2016, she is Vice Chairman of the Board and Director for Public Affairs of OSE immunotherapeutics.
Maryvonne is Vice Chairman of France Biotech, the French Association of Life Sciences entrepreneurs.
Maryvonne Hiance holds an Engineering Degree from the Ecole Polytechnique Féminine (Paris) and a Nuclear Engineering Degree from Polytech Grenoble (formerly the Institut des Sciences et Techniques Grenoble).
Location
Nantes, Pays de la Loire, France, Europe
Jobs history
0
N/A
Educations
1
N/A
Profile Resume
Maryvonne Hiance is the Vice Chairman and Director of Public Affairs at OSE Immunotherapeutics, based in Europe. With a background in Biotechnology, Maryvonne Hiance has a rich history of leadership and innovation. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.
Recommendation from your interest
N/A
Products and Innovations
0
There is no product and inovations for this profile.
Achievements
0
There is no Achievements for this profile.
Publications
0
There is no publication for this profile.
Recent Activity
There is no recent news or activity for this profile.